UAB17127:A phase Ib trial of fulvestrant, palbociclib (CDK4/6 inhibitor) and erdafitinib (JNJ- 42756493, pan-FGFR tyrosine kinase inhibitor) in ER+/HER2–/FGFR-amplified metastatic breast cancer (MBC)

Grant

Date/time Interval

  • August 17, 2018 - August 16, 2023

    • Awarded By

    Total Award Amount

  • 58980.00

    • Direct Costs

  • 45370.00

    • Sponsor Award Id

    • Contributor

  • cfalkson   Investigator  
  • grocque   Investigator  
  • strinem   Investigator  
  • cvaklava   Principal Investigator